Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
Innocan Pharma to Present at the 2024 ThinkEquity Conference
Innocan Pharma to Present at the 2024 ThinkEquity Conference
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Innocan Pharma Corporation Closes C$8.2 Million Private Placement with Institutional Investors
Innocan Pharma Corporation Announces C$8.2 Million Private Placement with Institutional Investors
Innocan Pharma Announces the Filing of a PCT Patent Application for its CBD Delivery System Technology in 153 Countries
Innocan Pharma Announces the Filing by Ramot at Tel Aviv University of an International Patent Application for its Unique Cannabinoids Loaded Exosome Delivery Platform (CLX)
Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021
Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University
Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)
Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss
Former Israeli Minister of Science and Technology and Highly Influential Venture Capitalist to Join Innocan Pharma's Advisory Committee
Innocan Pharma Announces Filing of International Patent Application for Topical Treatment for Diabetic Symptoms
Innocan Pharma and Health Investment Group S.A. Sign Exclusive Distribution Agreement for Poland
Clinical Study Validates Innocan Pharma's SHIR(R) CBD Eye Serum as an Anti-Puffiness Solution
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment
Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study
Innocan Pharma Among Leading CBD Pharma Companies to Participate at Lytham Partners Summer 2021 Investor Conference
Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study
Innocan Pharma Engages Lytham Partners to Lead Investor Relations and Shareholder Communication Program
Innocan Pharma and Polyflame Announce an Exclusive Distribution Agreement in France
Richard Serbin, Former Johnson & Johnson's VP and a Leading Global Strategy Advisor in the Healthcare Industry, to Join Innocan Pharma's Scientific Advisory Committee
Innocan Reports Q4 2020 Financial Results
Leading American Dermatologist Dr. Mitchell Kline to Join Innocan Pharma's Scientific Advisory Committee
Innocan Pharma Announces Proceeds of CDN $ 3.1M from the Exercise of Warrants Since January 1, 2021
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment
Innocan Pharma Announces the Completion of its First Full-Scale Manufacturing Run in the US and the Launching of its US Commercial Online Platform
Innocan Pharma Announces Proceeds of CDN $ 1.8M from the Exercise of Warrants Since December 1, 2020
Innocan Pharma Announces Successful Production of CBD Loaded Liposomes under Aseptic Conditions
Innocan Pharma Successfully Completes Large Scale Production of Exosomes
Innocan Pharma Announces the Launch of Its Commercial Website
Innocan Pharma Announces the Successful Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of Its Full-Scale Manufacturing Run in the USA